Vir Biotechnology Inc 2026年季度报告

FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period from___________toCommission File Number: 001-39083__________________________________________________ Vir Biotechnology, Inc.(Exact Name of Registrant as Specified in Its Charter) __________________________________________________ Registrant’s Telephone Number, Including Area Code: (415) 906-4324__________________________________________________ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filerNon-accelerated filer Accelerated filerSmaller reporting companyEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesNoAs of April29, 2026, the registrant had 168,651,974 shares of common stock, $0.0001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATIONItem 1.Financial Statements (unaudited)3Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025 (unaudited)3Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and 2025(unaudited)4Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2026and 2025 (unaudited)5Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2026and 2025 (unaudited)6Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025(unaudited)7Notes to Unaudited Condensed Consolidated Financial Statements8Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations21Item 3.Quantitative and Qualitative Disclosures About Market Risk29Item 4.Controls and Procedures30PART II.OTHER INFORMATIONItem 1.Legal Proceedings31Item 1A.Risk Factors31Item 2.Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities63Item 3.Defaults Upon Senior Securities63Item 4.Mine Safety Disclosures63Item 5.Other Information63Item 6.Exhibits65Signatures66 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantialrisks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q,including statements regarding our strategy, future financial condition, future operations, research and development, potential of, andexpectations for, our pipeline and technology platforms, the timing, potential of and expectations for ongoing and planned preclinicaland clinical studies, the timing and likelihood of regulatory filings and potential approvals for our product candidates, our ability tocommercialize our product candidates, the potential benefits of collaborations and in-licensing arrangements, projected costs,prospects, plans, objectives of management, expected market size and growth for our potential products, the timing of availability ofclinical data, program updates and data disclosures, and our plans for our portfolio, including our hepatitis delta virus and masked T-cell engager portfolios, are forward-looking statements. In some cases, you can identify forward-looking statements by terminologysuch as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,”“intend,” “may,” “might”, “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” andother similar expressions that are predictions o